{"id":963213,"date":"2026-05-14T17:47:19","date_gmt":"2026-05-14T21:47:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-reports-19-year-over-year-and-12-sequential-revenue-growth-bluebird-acquisition-integration-and-medicare-bei-pathway-position-company-for-continued-momentum\/"},"modified":"2026-05-14T17:47:19","modified_gmt":"2026-05-14T21:47:19","slug":"cbdmd-reports-19-year-over-year-and-12-sequential-revenue-growth-bluebird-acquisition-integration-and-medicare-bei-pathway-position-company-for-continued-momentum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-reports-19-year-over-year-and-12-sequential-revenue-growth-bluebird-acquisition-integration-and-medicare-bei-pathway-position-company-for-continued-momentum\/","title":{"rendered":"cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CHARLOTTE, N.C.\u00a0<\/span>, May 14, 2026<\/span> \/PRNewswire\/ — cbdMD, Inc. (NYSE American: YCBD), one of the nation’s leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its THC beverage brand Oasis, today announced financial results for the second quarter of fiscal year 2026, ended March 31, 2026.<\/p>\n

\n

\n
\n \"cbdMD
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The Company delivered 19% year-over-year and 12% sequential revenue growth, reflecting continued momentum in the core business and the contribution of newly acquired Bluebird Botanicals. Quarterly revenue, excluding revenue associated with the Bluebird acquisition, was the highest since our first fiscal quarter ending December 2023.<\/p>\n

“This was a quarter of meaningful execution on multiple fronts,” said Ronan Kennedy, CEO and CFO of cbdMD. “Our core business delivered another quarter of consistent growth, we successfully completed and integrated our first acquisition in years. The Bluebird Botanicals acquisition is a case study for what we can do \u2014 leveraging our infrastructure, marketing engine, and NYSE American listing to unlock value in a fragmented industry \u2014 and it sets the template for additional roll-up opportunities across hemp and adjacent health and wellness categories.”<\/p>\n

“At the same time, the regulatory backdrop has shifted more in the last few months than in any period I can recall,” Kennedy continued. “Multiple bipartisan legislative proposals are advancing, cannabis has been partially rescheduled, and CMS has opened the first federal Medicare pathway for hemp-derived CBD through the BEI program. We have been preparing for this moment for years. The launch of our clinical healthcare channel, our active engagement with ACOs, and our continued investment in patient science position cbdMD to participate meaningfully as adoption develops. We believe that as regulatory clarity continues to emerge, well-capitalized, compliance-focused operators with proven quality, safety data, and clinical credibility will be the ones that benefit \u2014 and that is precisely where cbdMD stands.”<\/p>\n

\n Highlights for the Second Quarter of Fiscal 2026 and Notable Business Updates<\/b>\n <\/p>\n